Table 1.
Immunohistochemical analysis of AMPK-β1 on an ovarian cancer tissue array (OVC1021, Pantomics, Inc.)
| |
|
AMPKβ1 expression [fold change] |
|
|
|---|---|---|---|---|
| Characteristics | Total | ≤ 3-fold | >3-fold | P |
| All cases |
97 |
57 (58.8) |
40 (41.2) |
|
| Stage |
|
|
|
|
| Early (1 + 2) |
73 |
37 (50.7) |
36 (49.3) |
|
| Late (3) |
24 |
20 (83.3) |
4 (16.7) |
0.008* |
| Grade |
|
|
|
|
| Low |
50 |
23 (46.0) |
27 (54.0) |
|
| High |
46 |
33 (71.7) |
13 (28.3) |
0.013* |
| Metastasis |
|
|
|
|
| No |
73 |
37 (50.7) |
36 (49.3) |
|
| Yes | 24 | 20 (83.3) | 4 (16.7) | 0.008* |
Clinicopathological analysis showed that down-regulated AMPK-β1 (≤3-fold) was associated with late stage (P = 0.008) and high-grade (P = 0.013) cancer and the presence of metastasis (P = 0.008). P, p-value. *, statistical significance.